Obesity programs: <li /> Phase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

A damaging trial failure in December wiped 70% off the share price of BioAge Labs, a US biopharma developing therapeutic ...

Lilly posed similar arguments to Novo’s, contending in a legal filing this week that compounded versions of tirzepatide—which is marketed under the brand names Mounjaro and Zepbound—aren’t ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

AMG 133 is a bispecific molecule that addresses two targets ... with Lilly’s dual GLP-1/GIP targeting drug tirzepatide, which is already approved for diabetes as Mounjaro and heading for ...

Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.

A GLP-1 agonist is a molecule that can suppress a patient's appetite by mimicking a hormone that indicates that the patient has eaten. Zepbound is a brand name for a drug based on tirzepatide ...

They have a similar mechanism of action (“MoA”) to Novo Nordisk A/S's (NVO) semaglutide and Lilly's tirzepatide ... a Phase 1 stage oral, small molecule GLP-1 receptor agonist, and CT-868 ...